NCT07479095 Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma
| NCT ID | NCT07479095 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione del Piemonte per l'Oncologia |
| Condition | Lepidic-Predominant Lung Adenocarcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-07-03 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2025-07-03 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates whether a 7-day ketogenic dietary regimen before 2-\[18F\]FDG PET/CT can improve the diagnostic accuracy of imaging in adults with suspected or histologically confirmed lepidic-predominant lung adenocarcinoma (LPA). LPA frequently shows low glucose metabolism and may yield false-negative FDG PET/CT results. Approximately 30 participants will undergo a tailored ketogenic diet for 7 days before PET/CT. Imaging results will be compared with histopathology and additionally assessed against literature-reported diagnostic performance and a matched retrospective institutional cohort.
Eligibility Criteria
Inclusion Criteria: * Written informed consent. * Age 18 years or older. * CT evidence of a lung nodule suspicious for LPA or lung biopsy positive for LPA. * Target nodule diameter at least 10 mm. * ECOG performance status 0 to 2. * Willingness and ability to adhere to a controlled ketogenic diet for 7 days. * Ability to comply with study procedures and visit schedule. Exclusion Criteria: * Not suitable for prolonged imaging procedures. * Renal failure. * Type 1 diabetes mellitus. * Pancreatitis. * Severe dyslipidemia. * Other malignancies that are progressing or required active treatment within the previous 3 years. * Serious or unstable medical, psychiatric, or substance use disorders that could interfere with study participation. * Pregnancy or breastfeeding. * Refusal to participate
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07479095 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lepidic-Predominant Lung Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07479095 currently recruiting?
Yes, NCT07479095 is actively recruiting participants. Contact the research team at alessio.rizzo@ircc.it for enrollment information.
Where is the NCT07479095 trial being conducted?
This trial is being conducted at Candiolo, Italy.
Who is sponsoring the NCT07479095 clinical trial?
NCT07479095 is sponsored by Fondazione del Piemonte per l'Oncologia. The trial plans to enroll 30 participants.